Goldman Sachs Starts Arcus Biosciences (RCUS) at Neutral

April 9, 2018 5:26 AM EDT
Get Alerts RCUS Hot Sheet
Price: $23.06 -2.99%

Rating Summary:
    10 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 15 | Down: 13 | New: 24
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Goldman Sachs initiates coverage on Arcus Biosciences (NYSE: RCUS) with a Neutral rating and a price target of $18.00.

Analyst Salveen Richter cites a relative lack of NT catalysts for coming out on the sideline.

For an analyst ratings summary and ratings history on Arcus Biosciences click here. For more ratings news on Arcus Biosciences click here.

Shares of Arcus Biosciences closed at $14.34 Friday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Goldman Sachs